<?xml version="1.0" encoding="UTF-8"?>
<fig id="Fig2">
 <label>Fig. 2</label>
 <caption>
  <p>Schematic representation of the in vitro experimental plan. GMP good manufacturing practice, ATMP advanced therapy medicinal product, IL interleukin, SCF stem cell factor, FBS fetal bovine serum, PDGF-bb platelet-derived growth factor type bb, GRO-α growth-regulated oncogene alpha, HGF hepatocyte growth factor, VEGF vascular endothelial growth factor, RANTES regulated on activation normal T cell expressed and secreted, MIP-1b macrophage inflammatory protein-1 beta, MCP-1 monocyte chemoattractant protein-1, LIF leukemia inhibitory factor, FACS fluorescence-activated cell sorting, CFU-EC colony forming unit-endothelial cell, Ac-LDL-Dil acetylated low-density lipoprotein labeled with dioctadecyl-tetramethylindocarbocyanine perchlorate, UEA-1 
   <italic>Ulex europaeus</italic> agglutinin-1
  </p>
 </caption>
 <graphic xlink:href="13287_2018_969_Fig2_HTML" id="MO2" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
